SELECT: Semaglutide in Overweight, Obesity With CV Disease, No Diabetes

In patients with preexisting cardiovascular disease and who are overweight or obese, but who do not have diabetes, 2.4 mg of subcutaneous semaglutide taken once weekly was superior to placebo in reducing the risk of cardiovascular death, myocardial infarction (MI) or stroke, according to findings from the SELECT trial presented at AHA 2023 and simultaneously published in the New England Journal of Medicine.

DAPA-MI: Dapagliflozin vs. Placebo in Patients With Acute MI

After approximately one year of treatment with dapagliflozin, patients with acute myocardial infarction (MI) experienced significant improvements in cardiometabolic outcomes but saw no significant benefits in the composite of cardiovascular death or hospitalization for heart failure (HF), based on findings from the DAPA-MI trial presented at AHA 2023 and simultaneously published in NEJM Evidence.

Single Dose of Lepodisiran Shows Promise in Lowering Lp(a) Over Extended Period

A single subcutaneous injection of lepodisiran, an siRNA targeting mRNA for the LPA gene, substantially lowered lipoprotein(a), or Lp(a), below baseline levels for 48 weeks, according to new late-breaking science presented at AHA 2023 and simultaneously published in JAMA.

ORBITA-2: Role of PCI in Stable Angina?

Compared with a placebo procedure, PCI resulted in a lower angina symptom score in patients with stable angina who were receiving little or no antianginal medication and had objective evidence of ischemia, based on findings from the ORBITA-2 trial presented at AHA 2023 and simultaneously published in the New England Journal of Medicine.

ARIES-HM3: With an LVAD, Is Aspirin Needed?

Avoidance of aspirin as part of an antithrombotic regimen that includes vitamin K antagonists (VKAs) in patients with advanced heart failure (AHF) treated with a fully magnetically levitated left ventricular assist device (FML-LVAD) is not inferior to a regimen containing aspirin, according to findings from the ARIES-HM3 trial presented at AHA 2023 and simultaneously published in JAMA.